Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran, a complex, branched polysaccharide with an average molecular weight of 40,000 daltons. Administered intravenously, it functions primarily as a plasma volume expander by increasing intravascular volume through its colloidal osmotic effect. Beyond volume expansion, Dextran 40 also improves microcirculation by reducing blood viscosity and inhibiting the aggregation and adhesiveness of erythrocytes and platelets. It is indicated for the adjunctive treatment of shock due to various causes such as hemorrhage, burns, surgery, or other trauma. Additionally, it is used as a priming fluid in pump oxygenators during extracorporeal circulation and for the prophylaxis of venous thrombosis and pulmonary embolism, particularly following high-risk surgical procedures like hip surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextran 40.